Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Bronchogen4 residuesAEDLEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: ADEL, Ala-Asp-Glu-Leu
Four amino acids long. That's the entire molecule. Bronchogen (AEDL) is a synthetic tetrapeptide bioregulator from Professor Vladimir Khavinson's research program in St. Petersburg, designed to target bronchial and pulmonary tissue at the gene expression level. Rat COPD models showed bronchial epithelial remodeling reversal after 30-day courses [1]. Zero human clinical trials exist, and all published data comes from a single research group. The oral capsule format (10 to 20 mg per day) makes it one of the few peptide bioregulators that doesn't require injection. A small but dedicated biohacker community follows the Khavinson cycling protocol for respiratory tissue support.
Does a four-amino-acid chain actually reach bronchial tissue and change gene expression? That's the core question behind Bronchogen, also known by its sequence Ala-Glu-Asp-Leu (AEDL), a synthetic tetrapeptide from the Khavinson Institute of Bioregulation and Gerontology in St. Petersburg. The proposed mechanism is direct DNA interaction. AEDL binds preferentially to CNG sequences in the major groove at N7 guanine positions, modulating transcription of genes tied to epithelial differentiation (NKX2-1, FOXA1, FOXA2), mucin production (MUC4, MUC5AC), and surfactant protein expression (SFTPA1). In vitro work confirmed the peptide increases DNA melting temperature by approximately 3.1 degrees Celsius [2]. The animal data is where things get interesting. Rat COPD models treated with month-long Bronchogen courses showed reversed bronchial epithelial remodeling, restored ciliated cell populations, normalized inflammatory cytokine profiles, and increased secretory IgA alongside surfactant protein B [1]. Those results came from Khavinson's group exclusively; no independent lab has replicated them. Real-world use stays oral. The standard protocol is 10 to 20 mg per day in enteric-coated capsules for 20 to 30 days, repeated every 4 to 6 months. Fewer than 50 indexed community reports exist as of April 2026. Reddit has no dedicated Bronchogen threads. Users who do take it typically slot it into broader Khavinson longevity stacks alongside Epithalon and Thymalin. Most report no perceptible short-term effects, which actually matches the epigenetic model: benefits, if real, would emerge weeks to months after a completed course.
Khavinson's bioregulation model proposes that short peptides bypass cell-surface receptors entirely. Instead, AEDL penetrates cell nuclei and binds directly to DNA, distinguishing between methylated and unmethylated regions at CNG sequences. The bronchial specificity comes from which genes the peptide accesses. In bronchial epithelial cells, AEDL binds promoter regions in the DNA major groove at N7 guanine positions. This interaction regulates transcription of epithelial differentiation factors including NKX2-1, SCGB1A1, FOXA1, and FOXA2. It also modulates mucin glycoprotein and surfactant protein expression. Downstream, the peptide shifts levels of Ki67 (proliferation), Mcl-1 (anti-apoptotic), p53 (tumor suppression), and NOS-3 (endothelial nitric oxide synthase). Effects are most pronounced in aged cell cultures [4]. Fluorescence-labeled peptide studies confirmed nuclear penetration of short peptides in this class [5]. In COPD rat models, the molecular cascade translated to measurable outcomes: reduced neutrophilic inflammation, restored epithelial barrier integrity, and recovery of secretory immune function through IgA upregulation [1]. One important caveat sits underneath all of this. Every mechanistic study traces back to a single research group. Independent replication of the DNA-binding model hasn't occurred in Western labs; the mechanism remains proposed rather than confirmed across multiple institutions.
All evidence is preclinical. Rat COPD models (26468022)[1] show bronchial epithelial remodeling reversal, ciliated cell restoration, IgA and surfactant protein B upregulation, and inflammatory cytokine normalization after month-long courses. In vitro: DNA stabilization (+3.1°C melting temperature) and tissue-specific gene expression modulation (NKX2-1, FOXA1/2, MUC4, MUC5AC, SFTPA1, Ki67, p53, NOS-3). No human RCTs published. All primary data originates from a single research group (Khavinson Institute, St. Petersburg). December 2024 MDPI study (Kononenko & Fedoreyeva) on ADEL in plant root development confirms DNA-interaction mechanism but has no clinical relevance.
PMID 30199201: anti-inflammatory and regenerative effect of Bronchogen in obstructive lung pathology rat model (Khavinson group, 2018); PMID 26468022: modulating effect on bronchial epithelium in COPD rats (2015)
Zero human RCTs; all data from one research group; oral bioavailability unpublished (~10–20% estimated); no independent replication of findings; Russian-language clinical documentation not indexed in English databases; publication bias from single-institute source cannot be excluded
Niche bioregulator community only. Near-zero Reddit presence (no dedicated threads on r/Peptides or r/longevity as of April 2026). Users follow Khavinson oral capsule protocols closely. A subset of US research-chemical community uses injectable form (lyophilized vial, SC), but dosing in this route has no published basis.
Community oral protocols mirror Khavinson manufacturer specifications exactly: strong alignment on dose and cycling structure. Divergence exists on injectable route: community sources (200 mcg–5 mg/day SC) have no published basis and represent extrapolation from non-Bronchogen peptide practices. Evidence quality gap (community belief vs. absence of human data) is the core misalignment.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | Daily |
Bronchogen is oral, so there's no reconstitution math for the standard protocol. Take 1 to 2 enteric-coated capsules (10 to 20 mg each) on an empty stomach, 15 to 20 minutes before breakfast. Swallow whole with water. Don't crush or open them; the enteric coating protects the peptide from gastric acid proteolysis. Without it, the tetrapeptide gets digested before reaching the small intestine. If you're using the injectable research vial route (no published basis, community convention only): reconstitute a 20 mg vial with 10 mL bacteriostatic water for a 2 mg/mL (2000 mcg/mL) concentration. At a 200 mcg dose, that's 10 units on a U-100 insulin syringe. At 500 mcg, that's 25 units. The non-obvious thing most beginners miss: don't expect to feel anything during the course. The proposed mechanism is epigenetic. Any subjective benefits, if they exist, typically show up weeks to months after finishing a course. Repeating courses more often than every 4 months overlaps the residual effect window and adds cost without documented extra benefit.
Standard bioregulator protocol: 20-30 day oral course (1-2 capsules daily), repeated every 4-6 months. Some protocols suggest two consecutive courses with a 1-week break for initial loading.
Cycling in the Khavinson bioregulator model is mechanistically driven, not a pharmacological safety precaution. The proposed mechanism is epigenetic: the ADEL tetrapeptide modulates gene transcription in bronchial epithelial cells, and these expression changes are proposed to persist 3–6 months after the peptide is cleared. Continuous daily dosing provides no incremental benefit once gene expression normalization is achieved: excess peptide is catabolized as its component amino acids (Ala, Asp, Glu, Leu). Cycling every 4–6 months is intrinsic to the mechanism.
Or use the universal Peptide Calculator for any peptide.
Expected: No subjective effects expected during the first week. Anecdotal respiratory comfort improvement occasionally reported by weeks 2–3. No validated human endpoints. Molecular effects (gene expression normalization) theorized to persist 3–6 months per Khavinson model.
Monitor: No mandatory labs: no validated biomarkers exist for Bronchogen in humans. Users tracking respiratory function may monitor SpO2 or spirometry (FEV1/FVC) before and 4–6 weeks post-course as an objective proxy.
Choose your dose: 10 mg (1 capsule) for a first course, 20 mg (2 capsules) for subsequent courses or the full Khavinson protocol.
Take capsules on an empty stomach, 15 to 20 minutes before your first meal of the day. Morning dosing is preferred.
Do not crush, chew, or open the enteric-coated capsules. The coating is required for the peptide to survive gastric acid.
Continue daily for 20 to 30 days (one full course).
After completing the course, wait 4 to 6 months before repeating. Some protocols suggest two consecutive 10-day courses with a 1-week break for initial loading.
Store capsules in original sealed packaging at 2 to 8 degrees Celsius, protected from light.
Reconstitute a 20 mg lyophilized vial with 10 mL bacteriostatic water. This gives 2 mg/mL (2000 mcg/mL).
Draw 10 units on a U-100 insulin syringe for a 200 mcg dose, or 25 units for 500 mcg.
Inject subcutaneously in the abdominal area using a 29 to 31 gauge needle.
Store reconstituted solution at 2 to 8 degrees Celsius and use within 24 hours per manufacturer guidance.
Oral Capsule Protocol (standard Khavinson route):
Injectable Research Route (community convention, no published data):
10–20 mg/day (base dose per Khavinson protocol)
Standard and only peer-reviewed route. Enteric coating protects peptide from gastric acid; absorption occurs in small intestine. Estimated oral bioavailability ~10–20%. All preclinical studies citing oral administration used this route.
Community sources suggest 200–500 mcg/day SC (vs. oral 10–20 mg/day). The ~40–100× dose reduction vs. oral reflects assumed higher SC bioavailability extrapolated from other peptides: no Bronchogen-specific PK data confirms this.
US research vendors sell Bronchogen as lyophilized 20 mg vials for research reconstitution. Example reconstitution: add 10 mL bacteriostatic water to 20 mg vial → 2 mg/mL (2000 mcg/mL) solution. At 200 mcg dose → 10 units on U-100 insulin syringe. No safety or efficacy data for injectable route exists.
Khavinson pineal tetrapeptide: standard longevity base stack. Combines systemic epigenetic bioregulation (Epithalon) with pulmonary tissue-specific support (Bronchogen). Co-administered in standard Russian multi-tissue protocols.
Sequential separate courses: not simultaneous daily dosing
Thymus bioregulator targeting immune T-cell maturation. Bronchogen upregulates secretory IgA in airways; Thymalin supports systemic cellular immunity: complementary immune modulation in the Khavinson multi-tissue framework.
Staggered separate 10–20 day cycles; not taken simultaneously
Khavinson brain/CNS bioregulator. Included in broader longevity stacks alongside organ-specific bioregulators. No direct mechanistic synergy with Bronchogen's bronchial action: stacking is protocol-structural (multi-organ coverage) rather than pharmacodynamic.
Broad immune modulator with documented antiviral and anti-inflammatory pulmonary activity (COVID-19 data). Some advanced users combine with Bronchogen for lung health goals: different mechanisms (receptor-mediated immune activation vs. epigenetic gene regulation). Community-level pairing only.
Bronchogen upregulates secretory IgA and modulates airway inflammatory cytokine profiles. Concurrent use with systemic immunosuppressants is unstudied and theoretically risks unpredictable immune dysregulation, particularly dangerous in transplant recipients.
Do not combineBoth Bronchogen and systemic steroids affect airway inflammatory pathways (NOS-3, cytokine profiles). Theoretical combinatorial effect is unstudied. Moderate inhaled corticosteroids (ICS) at standard doses are not expected to interact.
Pricing updated 2026-04-09
The biggest safety concern with Bronchogen isn't a specific adverse event. It's the absence of human safety data. Zero controlled clinical trials have been published. The entire published record comes from animal models, cell cultures, and molecular studies, all from a single institution. That means the side effect profile is incomplete by definition, not reassuring. In the preclinical literature, month-long Bronchogen courses in rat COPD models produced no documented systemic toxicity or organ damage [1]. Animal tolerability looked clean. But animal tolerability doesn't guarantee human safety, particularly for a peptide whose proposed mechanism involves direct DNA interaction and gene expression modulation. From the community side, the dataset is thin. Fewer than 50 indexed individual reports exist across forums, vendor review sections, and biohacker blogs. Within that small pool, oral Bronchogen is described as well tolerated. The most commonly mentioned complaint is mild gastrointestinal discomfort (bloating, mild nausea), typically occurring when capsules are taken with food rather than on an empty stomach 15 to 20 minutes before a meal. Adjusting timing resolves it for most users within 2 to 3 days. Because Bronchogen is a fully synthetic tetrapeptide (four standard L-amino acids: alanine, glutamic acid, aspartic acid, leucine), prion contamination concerns that apply to animal-derived tissue extracts don't apply here. Allergic reactions to capsule excipients remain theoretically possible. A separate risk category applies to the injectable route. Some US research vendors sell lyophilized Bronchogen vials (20 mg). A subset of users reconstitute these for subcutaneous injection at 200 to 500 mcg per day. No published pharmacokinetic, safety, or efficacy data supports injectable Bronchogen use at any dose. The community dosing conventions for SC administration are extrapolated from unrelated peptides. Injection-site reactions (redness, swelling, irritation) are possible with any subcutaneous peptide but haven't been systematically documented for Bronchogen specifically. Drug interactions are unstudied. Theoretical caution applies to immunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) because Bronchogen upregulates secretory IgA and modulates airway inflammatory cytokines. Combining it with systemic immunosuppressants could produce unpredictable immune effects. Standard inhaled corticosteroids at normal doses are not expected to interact. High-dose systemic corticosteroids (oral or IV prednisolone, dexamethasone) share overlapping inflammatory pathways (NOS-3, cytokine profiles) with Bronchogen, creating an unstudied theoretical interaction. Bronchogen should not be used during pregnancy or breastfeeding (no safety data). Children under 18 lack pediatric dosing or safety data. Active acute respiratory infections (bronchitis, pneumonia) represent another contraindication due to insufficient data on use during acute illness. Stop use and consult a physician if you experience allergic reactions (urticaria, significant GI distress), worsening respiratory symptoms, or fever during a course.
Verify Bronchogen dosing and safety with a second opinion
Two distinct product categories with different risk profiles: (1) Oral capsules from Khavinson licensees (CosmicNootropic, RuPharma): established manufacturers with reasonable track record, but no Western pharmacopeial standard or independent batch COA widely available. (2) US research lyophilized vials (Peptide Sciences, Core Peptides, Limitless Life Nootropics): >99% purity HPLC/MS verified, but no published safety or dosing data for SC Bronchogen use exists. Main risks are route-specific unknowns for injectable form and sourcing provenance for oral capsule form.
| Test | When | Target |
|---|---|---|
| Spirometry (FEV1, FVC, FEV1/FVC ratio) | Baseline before first course; 6 weeks post-course completion | FEV1/FVC >0.70 (normal); any improvement in ratio or FEV1% predicted in previously impaired users is a positive signal |
| SpO2 (resting and post-mild-exertion) | Daily during active course; weekly during residual effect window if tracking | Resting SpO2 ≥95%; post-exertion recovery to baseline within 2 minutes |
Objective pulmonary function measure: the most practical biomarker for evaluating Bronchogen's proposed bronchial tissue effects in a self-experimenter context. Track trends across cycles.
Simple non-invasive proxy for respiratory function; useful for trend tracking in users with known airway compromise. Not specific enough to confirm Bronchogen efficacy: use as supporting data only.
No noticeable effects expected. The peptide is beginning to interact with DNA in bronchial tissue and influence gene expression patterns at the molecular level.
Subtle changes in gene expression and protein synthesis may be underway. Some users anecdotally report easier breathing, though this hasn't been validated in controlled studies.
In animal models, measurable improvements in bronchial epithelium morphology and inflammatory markers are typically observed by the end of a 30-day course.
Bioregulator effects are theorized to persist beyond the active dosing period due to sustained changes in gene expression patterns.
Days 1 to 7, Early molecular phase: The peptide absorbs through intestinal transporters (PepT1/LAT) and theoretically distributes to bronchial epithelial tissue. Animal model data suggests DNA interaction begins right away, but nothing measurable changes at the cellular level this early. You won't feel anything. Some users notice mild GI discomfort (bloating or nausea) if they take the capsule with food instead of before a meal; it clears up by day 2 or 3. Days 8 to 20, Active course mid-phase: Per the Khavinson model, gene expression modulation continues: NKX2-1, FOXA1, and FOXA2 upregulation alongside inflammatory cytokine normalization and surfactant protein B increases. In animal models, histological improvements don't appear until the tail end of a 30-day course. Some users report subtle respiratory ease or reduced bronchial congestion starting around week 2. Not consistent across users, and no systematic data backs it up. Days 20 to 30, Course completion: Rat COPD data shows measurable bronchial epithelial remodeling reversal, ciliated cell restoration, and secretory IgA upregulation by the end of a 30-day course. Human equivalence is unestablished. Most users finish the course without noticing anything dramatic. Any subjective respiratory improvement, when reported, tends to be mild. 1 to 6 months post-course, Residual effect window: This is actually where the Khavinson model says the real action happens. Gene expression changes are proposed to persist 3 to 6 months after the peptide clears. Cumulative benefit builds across multiple annual cycles, according to the theory. Community reports of subjective respiratory resilience, fewer bronchial irritation episodes, and sustained breathing ease cluster in this window. Without controlled studies, causal attribution isn't possible.
Short peptide absorption via intestinal transporters (PepT1/LAT); theoretical distribution to bronchial epithelial tissue. Animal model data suggests molecular-level DNA interaction begins immediately, but no measurable histological or functional change expected at this stage.
Universally no perceptible effects. Occasional mild GI discomfort (bloating, nausea) if capsule taken with food rather than before a meal; resolves by day 2–3.
Continued gene expression modulation per Khavinson model (NKX2-1, FOXA1/2 upregulation; inflammatory cytokine normalization; surfactant protein B increase). Histological improvements in animal models emerge toward the end of month-long courses, not the first week.
Some users anecdotally report subtle subjective respiratory ease or reduced bronchial congestion from week 2 onward. Not consistent across users. No systematic data.
Rat COPD model data shows measurable bronchial epithelial remodeling reversal, ciliated cell restoration, and secretory IgA upregulation by end of 30-day course. Human equivalence unestablished.
Most users complete the course uneventfully. Any subjective respiratory improvement, when noted, is mild and inconsistent. No validated self-assessment endpoint without spirometry.
Khavinson epigenetic model proposes gene expression changes persist 3–6 months after peptide clearance. Cumulative benefit theorized to build across multiple annual cycles. No Bronchogen-specific RCT validates this timeline in humans.
Attributed benefits most commonly reported in this window: subjective respiratory resilience, fewer episodes of bronchial irritation, sustained breathing ease. Impossible to attribute causally without controls.
Source: Estimated from tetrapeptide class kinetics; no direct PK studies on Bronchogen published. Short-chain peptides of similar MW (~446 Da) typically have half-lives under 2 hours.
Loading the interactive decay curve.
Bronchogen holds no FDA approval and is classified as a research compound in the United States. It cannot be sold for human consumption under US federal law. Research chemical vendors list it as "for research purposes only" or "not for human use." In Russia, Bronchogen-containing products have been commercially available through Khavinson-licensed manufacturers as dietary supplements or parapharmaceuticals, not as prescription drugs. This classification does not transfer to Western jurisdictions. Athletes should note that while Bronchogen is not explicitly listed on the WADA Prohibited List, peptide bioregulators as a class could fall under Section S0 (non-approved substances) or Section S2 (peptide hormones) depending on interpretation. Athletes subject to anti-doping testing should consult their sport's governing body before use. Sourcing channels include Russian-licensed distributors (CosmicNootropic, RuPharma) for oral capsules and US research peptide vendors (Peptide Sciences, Core Peptides) for lyophilized vials. This content is for informational and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
